A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.

MLA

Houédé, Nadine, et al. “A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer.” The Oncologist, vol. 19, no. 12, Dec. 2014, pp. 1227–28. EBSCOhost, https://doi.org/10.1634/theoncologist.2014-0345.

APA

Houédé, N., Pulido, M., Mourey, L., Joly, F., Ferrero, J.-M., Bellera, C., Priou, F., Lalet, C., Laroche-Clary, A., Raffin, M. C., Ichas, F., Puech, A., & Piazza, P. V. (2014). A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer. The Oncologist, 19(12), 1227–1228. https://doi.org/10.1634/theoncologist.2014-0345

Chicago

Houédé, Nadine, Marina Pulido, Loic Mourey, Florence Joly, Jean-Marc Ferrero, Carine Bellera, Frank Priou, et al. 2014. “A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer.” The Oncologist 19 (12): 1227–28. doi:10.1634/theoncologist.2014-0345.